Literature DB >> 21309261

Pathologic and molecular features of uterine carcinosarcomas.

Maria-Angeles Lopez-Garcia1, Jose Palacios.   

Abstract

Uterine carcinosarcomas (UCSs), formerly known as malignant mixed müllerian tumors, are uncommon neoplasias that account for <5% of uterine malignancies. Traditionally, UCSs have been considered a subtype of sarcoma and the staging system and adjuvant oncological treatments used have been similar to those used for high-grade uterine sarcomas. However, there is now enough clinical, pathologic, and biological evidence to consider UCSs more closely related to high-grade endometrial carcinomas. Thus, these tumors should be staged based on the surgicopathologic staging system used for endometrial carcinomas. Morphologically, UCSs are heterogeneous biphasic tumors composed of an admixture of malignant (endometrioid and nonendometrioid) epithelial and (homologous and heterologous) mesenchymal elements in different proportions. UCSs predominantly metastasize as carcinomas and they are associated with a poor prognosis. Although stage is a consistent prognostic factor, the significance of several histopathological features, such as myometrial invasion, lymphovascular space involvement, type of carcinomatous component, extent of the sarcomatous component, and the presence of heterologous elements, remains controversial and probably differs among different stages. Although the diagnosis of UCS is not difficult in most cases, the differential diagnosis may include entities such as undifferentiated or dedifferentiated carcinoma, endometrioid adenocarcinoma with spindle cell elements, sarcomatous overgrowth in a low-grade müllerian adenosarcoma, and pure malignant mesenchymal tumors. Genetic and molecular studies have confirmed the clonal origin of most UCSs and have shown these tumors to be similar to those observed in high-grade/nonendometrioid carcinomas, with p53 mutations being the most common molecular alteration. Finally, from a biological standpoint, the process by which epithelial malignant cells of UCS transdifferentiate to malignant mesenchymal cells could be considered a true example of epithelial mesenchymal transition in human neoplasias.

Entities:  

Mesh:

Year:  2010        PMID: 21309261     DOI: 10.1053/j.semdp.2010.09.005

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  13 in total

Review 1.  [Un- and dedifferentiated endometrial carcinoma : A rare entity with a wide range of differential diagnosis].

Authors:  A K Höhn; C E Brambs; S Opitz; R Erber; A Hartmann; L-C Horn
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

Review 2.  A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus.

Authors:  W Glenn McCluggage
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

3.  Integrated Molecular Characterization of Uterine Carcinosarcoma.

Authors:  Andrew D Cherniack; Hui Shen; Vonn Walter; Chip Stewart; Bradley A Murray; Reanne Bowlby; Xin Hu; Shiyun Ling; Robert A Soslow; Russell R Broaddus; Rosemary E Zuna; Gordon Robertson; Peter W Laird; Raju Kucherlapati; Gordon B Mills; John N Weinstein; Jiashan Zhang; Rehan Akbani; Douglas A Levine
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

4.  Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).

Authors:  D Denschlag; F C Thiel; S Ackermann; P Harter; I Juhasz-Boess; P Mallmann; H-G Strauss; U Ulrich; L-C Horn; D Schmidt; D Vordermark; T Vogl; P Reichardt; P Gaß; M Gebhardt; M W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

Review 5.  [Grading of gynecological tumors : Current aspects].

Authors:  L-C Horn; D Mayr; C E Brambs; J Einenkel; I Sändig; K Schierle
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

6.  Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).

Authors:  Dominik Denschlag; Sven Ackermann; Marco Johannes Battista; Wolfgang Cremer; Gerlinde Egerer; Markus Follmann; Heidemarie Haas; Philipp Harter; Simone Hettmer; Lars-Christian Horn; Ingolf Juhasz-Boess; Karin Kast; Günter Köhler; Thomas Kröncke; Katja Lindel; Peter Mallmann; Regine Meyer-Steinacker; Alexander Mustea; Edgar Petru; Peter Reichardt; Dietmar Schmidt; Hans-Georg Strauss; Clemens Tempfer; Falk Thiel; Uwe Ulrich; Thomas Vogl; Dirk Vordermark; Paul Gass; Matthias W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-22       Impact factor: 2.915

7.  p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.

Authors:  Oluwole Fadare; Vinita Parkash
Journal:  Diagn Pathol       Date:  2017-11-14       Impact factor: 2.644

8.  miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.

Authors:  Jill H Tseng; Maria Bisogna; Lien N Hoang; Narciso Olvera; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; Douglas A Levine; Petar Jelinic
Journal:  Sci Rep       Date:  2017-06-15       Impact factor: 4.379

9.  Cytologic features of undifferentiated and dedifferentiated carcinomas of the endometrium.

Authors:  Amir-Hossein Akbari; Lu Wang; Robert A Soslow; Rajmohan Murali
Journal:  Cancer Cytopathol       Date:  2020-09-16       Impact factor: 5.284

Review 10.  Unique Molecular Features in High-Risk Histology Endometrial Cancers.

Authors:  Pooja Pandita; Xiyin Wang; Devin E Jones; Kaitlyn Collins; Shannon M Hawkins
Journal:  Cancers (Basel)       Date:  2019-10-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.